01—History
EPS (Diluted) History
Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2026. Drag across the bars to change the range.
- $2.78
5 older moves run past ±150% (largest +351.0%); point at, tap or drag across the bars to read one.
02—Ledger
EPS (Diluted), period by period
| Period | Scale | Value | Change | Source |
|---|---|---|---|---|
| FY2026 | $2.78 | +58.0% | 10-K | |
| FY2025 | $1.76 | +170.8% | 10-K | |
| FY2023 | $0.65 | +16.1% | 10-K | |
| FY2022 | $0.56 | −22.2% | 10-K | |
| FY2021 | $0.72 | −29.4% | 10-K | |
| FY2020 | $1.02 | −53.8% | 10-K | |
| FY2018 | $2.21 | +351.0% | 10-K | |
| FY2017 | $0.49 | +275.0% | 10-K | |
| FY2016 | −$0.28 | +78.9% | 10-K | |
| FY2013 | −$1.33 | −44.6% | 10-K | |
| FY2012 | −$0.92 | −258.6% | 10-K | |
| FY2011 | $0.58 | +168.2% | 10-K | |
| FY2010 | −$0.85 | +32.5% | 10-K | |
| FY2009 | −$1.26 | — | 10-K |
03—Questions
What is eps (diluted)?
Diluted earnings per share (EPS) can be defined as net income divided by the total number of shares outstanding including all dilutive securities such as stock options, warrants, and convertible bonds.
What is Exelixis's current eps (diluted)?
Exelixis (EXEL) annual eps (diluted) for 2026 was $2.78, a 57.95% increase from 2025. Exelixis eps (diluted) for the quarter ending October 2, 2026 was $0.85.
What was Exelixis's eps (diluted) in 2025?
Exelixis annual eps (diluted) for 2025 was $1.76, a 170.77% increase from 2023.
What was Exelixis's eps (diluted) in 2023?
Exelixis annual eps (diluted) for 2023 was $0.65, a 16.07% increase from 2022.
What is Exelixis's 5-year eps (diluted) CAGR?
Exelixis eps (diluted) grew at a compound annual growth rate (CAGR) of 31.02% from FY2021 to FY2026, going from $0.72 to $2.78 over 5 years.
- Company
- Exelixis
- Ticker
- EXEL
- Sector
- Healthcare
- Industry
- Biological Products, (No Diagnostic Substances)